Overview

Psilocybin in Cancer Pain Study

Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivative)
Phase:
PHASE2
Details
Lead Sponsor:
Yvan Beaussant, MD, MSci
Collaborators:
Cy Biopharma
Pancreatic Cancer North America
Treatments:
Psilocybin